Navigation Links
FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
Date:2/6/2008

ATLANTA, Feb. 6 /PRNewswire/ -- UCB today announced that the U.S. Food and Drug Administration (FDA) agreed to accept, for filing and review, a biologics license application (BLA) for Cimzia(R) (certolizumab pegol) for the treatment of adult patients with active rheumatoid arthritis (RA). Cimzia(R) is an investigational agent. If approved, Cimzia(R) will be the first and only PEGylated anti-TNF (Tumor Necrosis Factor) biologic therapy available for the treatment of rheumatoid arthritis.

"As a new anti-TNF, we believe that Cimzia(R) would provide an important new option for people living with this disease," said Olav Hellebo, President Inflammation Operations, UCB.

The BLA is based on data from more than 2,367 patients and includes three multi-center, placebo-controlled Phase III trials which were recently presented at the American College of Rheumatology (ACR) Annual Scientific Meeting.

In these studies, Cimzia(R), given with methotrexate, was shown to be significantly more effective than methotrexate alone for the inhibition of joint damage progression in patients with active RA as early as 24 weeks (RAPID 1 and RAPID 2). Cimzia(R) was shown to rapidly reduce the signs and symptoms of active RA with peak ACR50 and 70 responses achieved at 14 and 16 weeks. Improvement in physical function and quality of life measures were also seen for up to one year (RAPID 1). Further, Cimzia(R) administered as monotherapy showed significant improvement in signs and symptoms of RA from week 1, and this benefit was maintained through week 24 (Study 011). The most commonly occurring adverse reactions were headache, nasopharyngitis, and upper respiratory tract infections. Reported serious adverse reactions were infections (including tuberculosis) and malignancies (including lymphoma), consistent with findings from other trials in the anti-TNF class.

Preparation for submission of a Marketing Authorization Application (MAA) to the European Medicines Ag
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
2. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
5. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
6. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
8. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
11. AEterna Zentaris Announces Outcome of Managements Strategic Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... trained personnel, and detection dogs to safeguard airports ... revolutionary new electronic chip with nano-sized chemical sensors ... , The groundbreaking nanotechnology-inspired sensor, devised by Prof. ... of Chemistry and Center for Nanoscience and Nanotechnology, ... up the scent of explosives molecules better than ...
(Date:7/24/2014)... to materialise. Yet, scientists are making progress in ... One such approach relies on quantum dotsa kind ... electric field. A new study demonstrates that changing ... (TQDs) with electrical impulses can help better control ... be used as quantum information units, which would ...
(Date:7/24/2014)... to settle into equilibriuma state of unchanging balance ... of non-equilibrium conditions where new possibilities lie. Non-equilibrium ... such as temperature fluctuations, freezing and melting, or ... body temperature, airplanes to fly, and the Earth ... even though these conditions exist naturally and are ...
(Date:7/24/2014)... Research and Markets has announced the addition ... Market 2014-2018" report to their offering. ... the study of the gene and its functions and ... of proteomes or sets of proteins by using molecular ... mapping of genes and DNA sequencing to understand the ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2
... WA and VANCOUVER, Nov. 5 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals (NASDAQ: ... financial results will be released on Monday, November 10, ... and live webcast at 4:30,p.m. EDT that afternoon. Management ... update on the business and product pipeline., To ...
... 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX:ONC, NASDAQ:ONCY) ... results for the three and nine-month periods ... Decision, Oncolytics made a decision in ... randomized trial using the combination of REOLYSIN(R) ...
... N.J., Nov. 4 Cambrex,Corporation (NYSE: CBM ) reports third ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO ), -- Sales increased ... third quarter 2007. -- Adjusted EBITDA for the quarter was ... $9.7 million last year. -- Debt, net of cash was ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Release Third Quarter Financial Results 2Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 2Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 3Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 4Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 5Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 6Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 7Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 8Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 9Cambrex Reports Third Quarter 2008 Results 2Cambrex Reports Third Quarter 2008 Results 3Cambrex Reports Third Quarter 2008 Results 4Cambrex Reports Third Quarter 2008 Results 5Cambrex Reports Third Quarter 2008 Results 6Cambrex Reports Third Quarter 2008 Results 7Cambrex Reports Third Quarter 2008 Results 8Cambrex Reports Third Quarter 2008 Results 9Cambrex Reports Third Quarter 2008 Results 10Cambrex Reports Third Quarter 2008 Results 11Cambrex Reports Third Quarter 2008 Results 12Cambrex Reports Third Quarter 2008 Results 13Cambrex Reports Third Quarter 2008 Results 14
(Date:7/25/2014)... Neuregulin 1 (NRG1) is a pleiotropic factor characterized ... alternative splicing of exons that confer to the ... role for both the myelination occurring during development ... the peripheral nerve: axon degeneration, axon regrowth, remyelination ... Western Australia have discovered that the soluble NRG1 ...
(Date:7/25/2014)... development of diffusion tensor tractography (DTT), which is ... and estimation for three motor tracts, such as ... corticoreticular pathway became possible. The corticospinal tract is ... motor function in the human brain. Several studies ... by transtentorial herniation. In addition, some studies have ...
(Date:7/25/2014)... at the Stowers Institute for Medical Research ... receptors, and found pheromones crucial to triggering the mating ... receptors helps a male mouse detect pheromones that indicate ... receptors lets him know if the female mouse is ... are critical to trigger mating. Stowers, researchers believe mice ...
Breaking Biology News(10 mins):It takes two to court 2It takes two to court 3
... and Yuh Nung Jan, PhD, of the Howard Hughes ... will jointly receive the 2012 Neuroscience Prize of The ... contributions to the field of molecular neurobiology, particularly their ... activity and on how brain cells diversify and specialize ...
... Calif.) You pick up your cell phone and dial ... At. A. Time. Because you haven,t actually typed the number ... sequence of distinct movements. After dialing the number a ... a series of three successive bursts of movement: the area ...
... use plants as ,green phones, for communication with other ... same plants insects are also able to leave ,voicemail, ... via their effects on soil fungi. Researchers from the ... discovered this unique messaging service in the ragwort plant. ...
Cached Biology News:UCSF pair win Gruber Foundation Neuroscience prize 2UCSF pair win Gruber Foundation Neuroscience prize 3UCSF pair win Gruber Foundation Neuroscience prize 4Study by UC Santa Barbara psychologists reveals how brain performs 'motor chunking' tasks 2Study by UC Santa Barbara psychologists reveals how brain performs 'motor chunking' tasks 3Voicemail discovered in nature 2
... loxP-PGK-gb2-neo-loxP template is designed to allow ... cells. The loxP-PGK-gb2-neo-loxP template encodes ... a prokaryotic promoter (gb2) for expression ... a eukaryotic promoter (PGK) for expression ...
... depletion cocktail is tailored to ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... system. The CD4+ T cell ...
Standard Fluka For microscopy (Hist.) redox indicator...
... The VSOS-4 Orbital Shaker is designed ... to provide a uniform motion that is both ... The VSOS-4 Orbital Shaker provides a smooth, quiet, ... for a wide range of laboratory applications such ...
Biology Products: